Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases
The DOI matches its Crossref record.
Abstract
Patients with lysosomal storage diseases (LSDs) have a greatly diminished lifespan and reduced quality of life, particularly those with neurological manifestations. There are few therapeutic options available to treat the neurological signs and symptoms of LSDs. It is, therefore, imperative that efficacious and tolerable treatments are developed. Hematopoietic stem cell transplantation is carried out in some LSDs in which there is neurological involvement. However, this approach is associated with significant morbidity and mortality, and not all patients who receive this treatment exhibit improvements in cognitive signs and symptoms. A growing body of research in animal models of LSDs appears to support the efficacy of repeated delivery of recombinant lysosomal proteins via injection into the cerebrospinal fluid (CSF). Studies in dogs with mucopolysaccharidosis (MPS) Type 1 have shown that this approach enables widespread distribution of the recombinant protein within the brain, leading to a reduction in LSD pathology. Subsequent studies in MPS IIIA mice revealed that this strategy was also effective in ameliorating neuropathology and improving clinical signs in these animals. More recent studies in mice with Krabbe disease or a late infantile form of neuronal ceroid lipofuscinosis have demonstrated that delivery of recombinant proteins into the CSF may be efficacious in reducing disease pathology and neurological signs and symptoms. Whilst there are still important issues that need to be addressed, such as humoral immune responses to therapeutic protein administration and dose/ frequency selection, this approach represents a medium-term option for treating these devastating conditions. This review summarizes some of the findings and challenges ahead.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66778 · Cited by 215
“Preclinical studies of intrathecal delivery of a recombinant enzyme (39, 59–61), now being translated to humans (NCT01155778 and NCT01299727, clinicaltri-als.gov), confirm that an increase in sulfamidase levels in CSF can be effective in counteracting the pathological changes associated with MPS…”
Calias, P., Papisov, M., Pan, J., Savioli, N., Belov, V., Huang, Y., Lotterhand, J., Alessandrini, M., Liu, N., Fischman, A. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030341 · Cited by 133
“While much progress has been made in treating the somatic symptoms of MPS disorders [37], [38], development of a therapy for the devastating neurological involvement is greatly needed.”
BackgroundDrug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
“Hematopoietic stem cell transplantation has been used to treat many genetic diseases including lysosomal storage diseases (Hemsley & Hopwood, 2009).”
BackgroundLotfi, P., Tse, D. Y., Di Ronza, A., Seymour, M. L., Martano, G., Cooper, J. D., Pereira, F. A., Passafaro, M., Wu, S. M., & Sardiello, M. (2018) · Autophagy · doi:10.1080/15548627.2018.1474313 · Cited by 106
Papisov, M. I., Belov, V. V., & Gannon, K. S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300474m · Cited by 97
Metadata
- Authors
- Hemsley, K. M., & Hopwood, J. J.
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2009-12-23
- Volume
- 47 Suppl 1
- Pages
- S118-23
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2021058027
- Cited by
- 29
- References
- 0
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. https://app.cochat.ai/papers/10.5414/cpp47118
- The paper
- Hemsley, K. M., & Hopwood, J. J. (2009). Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cpp47118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.